159 related articles for article (PubMed ID: 33625041)
41. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
42. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
44. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
45. New designs for HIV-1 integrase inhibitors: a patent review (2018-present).
Taoda Y; Sugiyama S; Seki T
Expert Opin Ther Pat; 2023 Jan; 33(1):51-66. PubMed ID: 36750766
[TBL] [Abstract][Full Text] [Related]
46. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
Wood BR; Huhn GD
Open Forum Infect Dis; 2021 Dec; 8(12):ofab542. PubMed ID: 34877366
[TBL] [Abstract][Full Text] [Related]
47. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Leonard MA; Cindi Z; Bradford Y; Bourgi K; Koethe J; Turner M; Norwood J; Woodward B; Erdem H; Basham R; Baker P; Rebeiro PF; Sterling TR; Hulgan T; Daar ES; Gulick R; Riddler SA; Sinxadi P; Ritchie MD; Haas DW
Clin Infect Dis; 2021 Oct; 73(7):e2153-e2163. PubMed ID: 32829410
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review.
O'Kelly B; Murtagh R; Lambert JS
Ther Drug Monit; 2020 Apr; 42(2):229-244. PubMed ID: 32004247
[TBL] [Abstract][Full Text] [Related]
49. Summary for Patients: Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV.
Ann Intern Med; 2021 Jun; 174(6):I21. PubMed ID: 33721514
[No Abstract] [Full Text] [Related]
50. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
De Clercq E
Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
[TBL] [Abstract][Full Text] [Related]
51. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
52. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy.
Lake JE; Wu K; Bares SH; Debroy P; Godfrey C; Koethe JR; McComsey GA; Palella FJ; Tassiopoulos K; Erlandson KM
Clin Infect Dis; 2020 Dec; 71(9):e471-e477. PubMed ID: 32099991
[TBL] [Abstract][Full Text] [Related]
53. Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
Fuller T; Fragoso da Silveira Gouvêa MI; Benamor Teixeira ML; Ferreira Medeiros A; Amorim da Silva P; Medeiros Braga C; Constan Werneck Sant'anna M; de Mattos Salgueiro M; da Silveira Bressan C; Mendes-Silva W; João EC
HIV Med; 2023 Mar; 24(3):301-310. PubMed ID: 36065478
[TBL] [Abstract][Full Text] [Related]
54. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
55. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.
Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
Viruses; 2021 Jan; 13(2):. PubMed ID: 33572956
[TBL] [Abstract][Full Text] [Related]
56. Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug.
Pantazis N; Papastamopoulos V; Antoniadou A; Adamis G; Paparizos V; Metallidis S; Sambatakou H; Psichogiou M; Chini M; Chrysos G; Panagopoulos P; Sipsas NV; Barbunakis E; Gogos C; Touloumi G;
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016299
[TBL] [Abstract][Full Text] [Related]
57. Changes in renal and metabolic indices after switching from tenofovir disoproxil fumarate- to tenofovir alafenamide-containing ART among individuals with HIV in Canada: A retrospective study.
Shokoohi M; Gupta M; Crouzat F; Smith G; Kovacs C; Brunetta J; Chang B; Knox D; Acsai M; Merkley B; Giolma K; Fletcher D; Loutfy M
Int J STD AIDS; 2021 Aug; 32(9):861-871. PubMed ID: 33890817
[TBL] [Abstract][Full Text] [Related]
58. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Gomez M; Seybold U; Roider J; Härter G; Bogner JR
Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
60. HIV integrase inhibitors: 20-year landmark and challenges.
Métifiot M; Marchand C; Pommier Y
Adv Pharmacol; 2013; 67():75-105. PubMed ID: 23885999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
